drugset / Trial / NCT05606263
Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluated the efficacy and safety of caldonirimab plus nimotuzumab as second-line or later therapy for recurrent or metastatic cervical cancer
Timeline
- Start
- 2022-11-01
- Primary completion
- 2023-11-30
- Completion
- 2025-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Caldonirimab | Monoclonal antibody | 6 mg/kg | — |
| Subject | Nimotuzumab | Monoclonal antibody | 400 mg | Intravenous |